依西美坦联合卵巢功能抑制治疗在高复发风险绝经前乳腺癌中的应用价值OA
Clinical Value of Exemestane Combined with Ovarian Function Suppression in Premenopausal Breast Cancer at High Risk of Recurrence
目的:探讨依西美坦联合卵巢功能抑制(OFS)用于高复发风险绝经前乳腺癌的临床疗效与安全性,分析其对卵巢功能、肿瘤标志物及炎症因子水平的影响.方法:回顾性选取 2023 年1月~2024年 6 月本院收治的 90 例高复发风险绝经前乳腺癌患者,按治疗方案分为对照组(44例,单纯OFS治疗)与观察组(46 例,依西美坦联合OFS治疗),两组均连续治疗 6 个疗程.比较两组治疗前后卵巢功能指标[雌二醇(E2)和卵泡刺激素(FSH)]、肿瘤标志物[癌胚抗原(CEA)和β2-微球蛋白(β2-MG)]、炎症因子[白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)和白介素-8(IL-8)]水平,并随访统计无进展生存期(PFS)、1年累计生存率、生活质量[采用卡尔诺夫斯基功能状态量表(KPS)进行评估]及不良反应发生率.结果:治疗后,观察组FSH和KPS评分均高于对照组(P<0.05);E2、CEA、β2-MG、IL-2、TNF-α和IL-8均低于对照组(P<0.05).观察组平均PFS长于对照组,1年累积生存率高于对照组(P<0.05).两组皮疹、胃肠道反应、关节疼痛、肝肾功能损伤发生率比较均无统计学差异(P>0.05).结论:依西美坦联合OFS治疗可有效降低高复发风险绝经前乳腺癌患者的雌激素水平,延长PFS,提高生活质量.
Objective:To evaluate the efficacy and safety of exemestane combined with ovarian function suppression(OFS)in premenopausal patients with breast cancer at high risk of recurrence and to assess its effects on ovarian function,tumor marker levels,and inflammatory factor levels.Methods:We retrospectively included 90 premenopausal patients with breast cancer at high risk of recurrence who were treated at our hospital between January 2023 and June 2024.According to the treatment regimen,patients were assigned to the control group(n=44;OFS alone)or the observation group(n=46;exemestane combined with OFS).Both groups received 6 consecutive courses of treatment.Ovarian function indicators[estradiol(E2)and follicle-stimulating hormone(FSH)],tumor markers[carcinoembryonic antigen(CEA)and β2-microglobulin(β2-MG)],and inflammatory factors[interleukin-2(IL-2),tumor necrosis factor-α(TNF-α),and interleukin-8(IL-8)]were compared between the two groups before and after treatment.Patients were followed,and progression free survival(PFS),the 1-year cumulative survival rate,quality of life[assessed using the Karnofsky Performance Status scale(KPS)],and the incidence of adverse reactions were recorded.Results:After treatment,FSH levels and KPS scores were higher in the observation group than in the control group(P<0.05),whereas E2,CEA,β2-MG,IL-2,TNF-α,and IL-8 levels were lower(P<0.05).Mean PFS was longer and the 1-year cumulative survival rate was higher in the observation group than in the control group(P<0.05).No significant between-group differences were observed in the incidences of rash,gastrointestinal reactions,arthralgia,or hepatic and renal function impairment(P>0.05).Conclusion:Exemestane combined with OFS effectively reduces estrogen levels,prolongs PFS,and improves quality of life in premenopausal patients with breast cancer at high risk of recurrence.
王玉龙;王亚茜;鲍冬冬;周楠
河南科技大学第二附属医院,洛阳 471400河南科技大学第二附属医院,洛阳 471400河南科技大学第二附属医院,洛阳 471400河南科技大学第二附属医院,洛阳 471400
医药卫生
乳腺癌绝经前高复发风险卵巢功能抑制依西美坦
breast cancerpremenopausehigh risk of recurrenceovarian function suppressionexemestane
《中国合理用药探索》 2026 (8)
22-27,6
河南省医学科技攻关计划项目(LHGJ20200933)
评论